$PLUR News
Last published 3d ago
- 3d agoPLURPluri Adds ISO 9001 and ISO 13485 Certifications to Support PluriCDMO Commercial ExpansionGlobeNewswireHAIFA, Israel, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq, TASE: PLUR) ("Pluri" or the "Company"), a biotechnology company advancing cell-based solutions for health and longevity, today
- 2w agoPLURPluri to Host Investor Conference Calls to Discuss Updates and Strategic DevelopmentsGlobeNewswireHAIFA, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq and TASE: PLUR) ("Pluri" or the "Company"), a biotechnology company advancing cell-based solutions for health and longevity, will
- 2w agoPLURZEOXPluri and ZEO ScientifiX Partner to Expand U.S. Manufacturing and Commercial Platform for Regenerative MedicineGlobeNewswireEstablished U.S. commercial platform: ZEO contributes biologics manufacturing, scientific expertise, an existing product portfolio, physician relationships, and dedicated sales, marketing, and educational
- 3w agoPLURPluri Chairman and Active Investor Alejandro Weinstein to Acquire EIB Loan, in Strong Vote of Confidence in the CompanyGlobeNewswireHAIFA, Israel, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq, TASE: PLUR) ("Pluri" or the "Company"), a biotechnology company advancing cell-based solutions in regenerative medicine and
- 1mo agoPLUREver After Foods and Roslin Technologies Achieve Major Leap in Cultivated Meat ProductivityGlobeNewswireHAIFA, Israel and EDINBURGH, Scotland, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Ever After Foods (EAF) and Roslin Technologies today announced results from their joint cultivated meat production program. Combining Roslin
- 2mo agoPLURPluri Announces Pricing of $3.3 Million Registered Direct Offering and Concurrent Private Placement with a Single Healthcare Focused Institutional InvestorGlobeNewswireHAIFA, Israel, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri"), a biotechnology company, leveraging its proprietary three-dimensional ("3D") cell expansion platform
- 2mo agoPLURPluri's Ever After Foods Expands Cultivated-Protein Platform Through Fishway Acquisition and Strategic InvestmentGlobeNewswireEver After Foods secures an additional $2 million strategic investment supporting ongoing platform development and commercialization activities. HAIFA, Israel, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Pluri Inc.
- 2mo agoPLUREver After Foods Acquires Fishway to Expand Integrated Food Production Technology PlatformGlobeNewswireHAIFA, Israel, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Ever After Foods (EAF) today announced the strategic acquisition of Fishway, representing an important milestone in the company's long-term strategy to expand its
- 3mo agoPLURPluri Advances Commercial Expansion Through Its Subsidiary Cellav, Completing Regulatory Registration in the UKGlobeNewswireUK regulatory registration supports commercial launch of regenerative aesthetics portfolio in a market with an estimated size of ~$900 million annually, and strengthens the foundation for broader international expansion
- 4mo agoPLURPluri Chairman Alejandro Weinstein’s Cumulative Investment Exceeds $17 Million, Ownership Surpasses 30%GlobeNewswireHAIFA, Israel, July 14, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq, TASE: PLUR), a biotechnology company leveraging a proprietary cell-based platform across multiple commercial verticals, today provided an update on
- 5mo agoPLURPluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products ListingGlobeNewswireTwo regenerative aesthetic and longevity products, with clinically validated ingredients, are expected to reach the U.S. market during 2026, entering a rapidly expanding U.S. medical aesthetics market, projected to reach
- 7mo agoPLURPluri Secures Additional Investment from Chairman Alejandro Weinstein at 30% Premium to Market in a Private PlacementGlobeNewswireHAIFA, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- Pluri Inc.
- 8mo agoPLURPluri Secures Global IP Position with China Patent Grant for Large-Scale Immune Cell Expansion, Complementing Prior U.S. PatentGlobeNewswireExpands patent protection across major global pharmaceutical markets, including the U.S., China and Asia-Pacific Enables scalable, automated manufacturing of diverse immune cell therapies using proprietary 3D expansion
- 9mo agoPLURPluri Successfully Completes First Phase of Resbiomed Program for Placenta-Derived Collagen-Rich BiomaterialsGlobeNewswireHAIFA, Israel, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Pluri, Inc.
- 10mo agoPLURPluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing AchievedGlobeNewswireHAIFA, Israel, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Pluri, Inc.
- 11mo agoPLURPluri Appoints Alejandro Weinstein as Chairman of the Board to Lead Strategic Shift and Unlock Value, Backed by Additional InvestmentGlobeNewswireWeinstein brings a global track record of transforming companies through value unlocking, and participation in over 20 M&A transactions and more than $5 billion in exits across healthcar
- 12mo agoPLURPluri and Subsidiaries Earn Multiple Industry Honors, Named as Overall BioAgriculture Company of the YearGlobeNewswireHAIFA, Israel, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Pluri Inc.
- 1y agoPLURPluri Partners with Miss Universe Skincare Introducing Exosome-Enhanced Regenerative SkincareGlobeNewswirePluri launches wholly-owned health and aesthetics subsidiary Cellav- leveraging Pluri's proprietary 3D cell expansion platform to deliver advanced exosome-based technologies for medical aesthetics
- 1y agoPLURLeading Global Players Back and Fund Pluri's Cell-Based Food and Agriculture CollaborationsGlobeNewswirePluri entered strategic collaborations across Asia, Europe and the United States ("U.S.") to transform food and agriculture production via its subsidiaries' advanced cell expansion technologies
- 1y agoPLURPluri Subsidiary Coffeesai and Instituto del Café de Chiapas Announce Strategic Collaboration to Advance Cell-Based Coffee Manufacturing in MexicoGlobeNewswireState-backed collaboration outlines a multi-phase, capital-light path from cell line development to pilot-scale biofarming
- 1y agoBCLIPLURBrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical TrialsPR NewswireBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced...
- 1y agoPLURPluri CEO Issues Shareholder Letter Highlighting Strategic Growth, Innovation, and Global Market ExpansionGlobeNewswireMajor milestones include entry into cultivated cacao and coffee markets and progress toward commercial-scale productionCompany reports nearly 4
- 1y agoPLURPluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd.GlobeNewswireAcquisition of approximately 71% stake in Kokomodo Ltd.Acquisition uniquely combines Pluri's mass-scale cell production expertise with Kokomodo Ltd.'s ability to craft real, controlled, climate-resilient cacao using
- 1y agoPLURPluri Announces Expansion of Intellectual Property Portfolio with Two Granted Patents for 3D Expansion of Immune Cells in the United States and IsraelGlobeNewswireLatest granted patents reinforce Pluri's position as a leader in Mucosal-Associated Invariant T ("MAIT") cell-based cell therapies for solid cancersPluri's MAIT platform enables commercial scale production of powerful
- 1y agoPLURPluri Announces Exclusive Collaboration Agreement with Hemafund to Enhance Ukraine's Radiation Emergency PreparednessGlobeNewswireStrategic initiative to address Ukraine's urgent need for radiation countermeasures Hemafund's infrastructure ensures secure storage and rapid deployment of emergency treatments Collaboration may potentially generate
- 1y agoPLUREver After Foods and Bühler Collaborate to Scale Cultivated Meat Production and DistributionGlobeNewswireKEMPTTHAL, Switzerland and HAIFA, Israel, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Foodtech innovator Ever After Foods (EAF) and global food leader Bühler today announced an expansive cultivated meat collaboration to help
- 1y agoPLURPluri Secures Additional $3.5 Million Investment from Major Shareholder at Premium to Market, Bringing Total Recent Financings to $10 MillionGlobeNewswireNew investment follows recent private placement of $6.5 million with global investor and entrepreneur, Mr. Alejandro WeinsteinFunds are intended to support Pluri's growth and execution strategy as a global leader in
- 1y agoPLURPluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host DiseaseGlobeNewswireHAIFA, Israel, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri" or the "Company"), an innovator in the development of leading cell-based technologies for various indications,
- 1y agoPLURPluri Shortlisted for CDMO of the Year Award by Advanced Therapies Awards 2025GlobeNewswireHAIFA, Israel, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE:PLUR) ("Pluri" or the "Company"), a leading biotechnology company leveraging its proprietary platform for cell-based solutions
- 1y agoPLURPluri Evaluates Readiness for Mass Production of PLX-R18 for Acute Radiation Syndrome Amid Rising Nuclear Threat ConcernsGlobeNewswireHAIFA, Israel, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri" or the "Company"), a biotechnology company leveraging its proprietary platform for cell-based solutions to create a
- 2y agoPLURPluri Inc. to Present at November 21st Virtual Investor Summit Microcap EventACCESS NewswireHAIFA, ISRAEL / ACCESSWIRE / November 12, 2024 / Pluri Inc. , a leading biotechnology company that offers cell-based solutions for various industries. The company will be available for 1-on-1 meetings
- 2y agoBCLIPLURBrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial ManufacturingPR NewswireBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that it...
- 2y agoPLURPluri Collaborates with Bar-Ilan University to Advance Cancer Immunotherapy for Solid Tumors, Supported by Israel Innovation AuthorityGlobeNewswireThe Israel Innovation Authority will fund Pluri and BIRAD's collaboration to advance MAIT Cell Therapy, led by Professor Cyrille Cohen, Head of the laboratory of tumor immunology and immunotherapy at Bar-Ilan
- 2y agoPLURPluri's CDMO Selected to Manufacture Kadimastem's Novel Cell Therapy Product CandidatesGlobeNewswireHAIFA, Israel, July 18, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company Pluri Inc. (NASDAQ:PLUR) (TASE:PLUR) ("Pluri" or the "Company"), which transforms cells into solutions that promote global
- 2y agoPLURPluri Announces €1 Million Proof of Concept Agreement to Enhance Global Sustainable Vegetable SupplyGlobeNewswireHAIFA, Israel, July 08, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company Pluri Inc. (NASDAQ:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), which transforms cells into solutions that promote global
- 2y agoPLURPluri Subsidiary Ever After Foods Secured $10 Million Strategic Investment to Solve Cultivated Food Scalability ChallengesGlobeNewswire$10 million funding round from U.S. and EU strategic investors, will accelerate growth and empower efficient cultivated meat, fish and seafood production at global scale, potentially tackling significant scalability
- 2y agoPLURU.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri's PLX-R18 Acute Radiation Syndrome ContractGlobeNewswireAs part of Pluri's previously announced $4.2 million 3-year contract with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), the option for the second year of the contract has been exercised to fund
- 2y agoPLURNovel Medical Food Solution for the Elderly: Pluri & Wilk Collaborate to Develop Human Breast Milk-Derived Food Production on a Commercial ScaleGlobeNewswireNew production process will be developed based on Pluri's proprietary 3D cell expansion technologyHuman breast milk oligosaccharides are known to shape the gut microbiota and thus provide health benefits to adultsGlobal
- 2y agoPLURUnleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Cancer TreatmentGlobeNewswirePlacental Mucosal Associated Invariant T (MAIT) cells are unique unconventional immune T cells which are particularly suitable for the treatment of solid tumors, a significant unmet medical needMAIT cells offer unique
- 2y agoPLURBreakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New MethodGlobeNewswirePluri's patent enables mass-scale production of immune cell therapiesNew patented technology is applicable for the expansion of a variety of immune cellsTechnology sets stage for potential immune cell therapy
- 2y agoPLURPluri's Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming ConferencesGlobeNewswireHAIFA, Israel, March 28, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), a leading biotechnology company that transforms cells into solutions that promote
- 2y agoPLURPluri Inc. Announces 1-for-8 Reverse Share SplitGlobeNewswireHAIFA, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri" or the "Company"), a leading biotechnology company that transforms cells into solutions, today announced that
- 2y agoPLURPluri's Sustainable Cell-Based Coffee Addresses Critical Challenges Revealed in International Coffee Organization Market ReportGlobeNewswireInternational Coffee Organization (ICO) Market Report published on March 7, 2024 highlights alarming price instability challenging the coffee industryAccording to the report, adverse weather conditions, first noted in
- 2y agoPLUREngage with Pluri's Talent: Exciting Conference Appearances AheadGlobeNewswireHAIFA, Israel, March 19, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), a leading biotechnology company that transforms cells into solutions that promote
- 2y agoPLURPluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug ManufacturingGlobeNewswireHAIFA, Israel, March 14, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), a leading biotechnology company that transforms cells into solutions, today announced
- 2y agoPLURPluri™ Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell CultivationGlobeNewswireHAIFA, Israel, March 11, 2024 (GLOBE NEWSWIRE) -- In a strategic move that underscores its innovative edge in the agtech sector, Pluri Inc. (NASDAQ:PLUR) (TASE:PLUR) ("Pluri" or "the Company") today
- 2y agoPLURPluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory BoardGlobeNewswireHAIFA, Israel, March 06, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri" or the "Company"), a leading biotech company that transforms cells into solutions that promote global wellbeing and
- 2y agoPLURPluri's Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 GoalsGlobeNewswireGrowing pipeline of industry-specific new potential products, services, collaborations and partnerships through PluriAgtech, PluriCDMO, PluriHealth, and PluriFoodRecent achievements include: new cell-based coffee
- 2y agoPLURStep into the Future: Pluri Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee CrisisGlobeNewswirePluri to leverage its proprietary 3D technology platform to develop cell-based products for the coffee industry under its new business vertical PluriAgtechThe rapidly growing $130 billion coffee industry is at risk as
- 2y agoPLURPluri Launches Advanced Global Cell Therapy Contract Development and Manufacturing OrganizationGlobeNewswirePluri, an established global leader in the development and manufacturing of cell-based therapeutics, launches new revenue-generating Contract Development and Manufacturing Organization (CDMO) division.PluriCDMO™